DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for proliferative diabetic retinopathy — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProliferative diabetic retinopathy maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside proliferative diabetic retinopathy in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
TetR(D) — Minocycline has a real, experimentally solved structure in complex with this target (PDB 2XPV, 1.49 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet miydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2XPV · 1.49 Å · ligand Minocycline (MIY). Experimental structure, not a prediction.
What the evidence adds up to
In a 2006 proteomic study of vitreous samples from 15 patients with proliferative diabetic retinopathy and active neovascularisation, eight proteins were found to be significantly differentially expressed compared to age-matched patients with macular hole. Five of those proteins were upregulated and three were downregulated. The authors identified pigmented epithelium derived factor, serine protease inhibitor, apolipoprotein A-IV precursor, prostaglandin-H2 D-isomerase, alpha-1-antitrypsin precursor, ankyrin repeat domain 15 protein, alpha2-HS-glycoprotein, and beta V spectrin as candidate proteins potentially involved in the pathogenesis of proliferative diabetic retinopathy. No clinical outcomes such as visual acuity or regression of neovascularisation were reported.
A 2013 editorial on diabetic retinopathy mechanism research described the pathogenesis as a vast network of multiple factors, including unifying mechanisms, inflammatory reaction, neuron degeneration, and metabolic memory of glucose, alongside four established pathogenic molecular pathways. The editorial stated that these lines of research may represent only one corner of the iceberg and that enormous challenges remain. It suggested that collaboration across disciplines and searching for novel therapy targets might yield unexpected benefits for basic research.
A 2024 editorial discussing a review by Morya et al on diabetic retinopathy noted recent advancements and ongoing challenges. It highlighted the importance of those advancements and emphasised the need for continued research and innovation for enhanced management. The editorial underscored the potential of emerging therapies for improving patient outcomes but provided no new data, no drug names, and no quantitative results.
What is still missing is a clinical trial that tests any of the eight differentially expressed vitreous proteins as a therapeutic target in patients with active proliferative diabetic retinopathy. No drug has been repurposed or trialled on the basis of these proteomic findings. The 2024 editorial offers no new evidence, and the 2013 editorial explicitly warns that current mechanistic understanding may be incomplete. Funding for a properly powered, stratified trial that measures regression of neovascularisation and visual outcomes is absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Eye Research · 2006 · 54 citations
Differential Expression of Vitreous Proteins in Proliferative Diabetic Retinopathy
AbstractPURPOSE: To identify vitreous proteins that were differentially expressed in patients suffering from proliferative diabetic retinopathy with active neovascularization. METHODS: The vitreous samples of 15 active proliferative diabetic retinopathy patients were analyzed by two-dimensional gel electrophoresis and mass spectrometry, and the results were compared with those from age-matched patients with macular hole. RESULTS: Twenty-five protein spots were identified in the two-dimensional gel electrophoresis gels. Eight proteins (pigmented epithelium derived factor, serine protease inhibitor, apolipoprotein A-IV precursor, prostaglandin-H2 D-isomerase, a(1)-antitrypsin precursor, ankyrin repeat domain 15 protein, alpha2-HS-glycoprotein, and beta V spectrin) in the 25 spots were expressed significantly differently between the macular hole and proliferative diabetic retinopathy patients (p value < 0.05). Five proteins were upregulated in the proliferative diabetic retinopathy patients, and three were downregulated (p value < 0.05). CONCLUSIONS: We constructed vitreous protein profiles for proliferative diabetic retinopathy patients and identified eight candidate proteins believed to be involved in the pathogenesis of proliferative diabetic retinopathy.
World Journal of Methodology · 2024 · 3 citations · open access
Advancements in diabetic retinopathy: Insights and future directions
AbstractThis editorial discusses recent advancements and ongoing challenges in diabetic retinopathy, as reviewed by Morya et al in their comprehensive analysis. In their review, Morya et al discussed the pathophysiology of diabetic retinopathy and explored novel treatment modalities. This editorial highlights the importance of these advancements and emphasizes the need for continued research and innovation for the enhanced management of diabetic retinopathy. It also reflects upon the implications of the authors’ review findings for clinical practice and future research directions, underscoring the potential of emerging therapies for improving patient outcomes and providing a deeper understanding of disease mechanisms.
Indian Journal of Pharmaceutical Sciences · 2021 · 2 citations · open access
Analysis of the Clinical Efficacy of Minocycline in the Treatment of Diabetic Retinopathy
AbstractMinocycline has been proven to reduce oxidative stress. This article further explores the safety and clinical efficacy of minocycline in the treatment of diabetic retinopathy. Selected 60 patients with diabetic retinopathy admitted to our hospital and divided them into two groups, observation group (30 cases) and control group (30 cases) randomly. Both groups received conventional treatment. Then treated control group with calcium dobesilate capsule and rosuvastatin calcium tablet. As well as the same drugs in control group, observation group received minocycline and the treatment period was 60 d. Compared visual acuity score, diabetic retinopathy stage, retinal neovascularization fluorescein leakage area, incidence of complications and adverse drug reactions with both groups after treatment. The vision improvement of observation group was remarkably higher than control group (p<0.05); The incidence of retinopathy stage III in control group was 36.7 %, which was higher than 13.3 % of observation group (p<0.05); After treatment, the retinal neovascularization fluorescein leakage area decreased to 241.3±12.44 mm2 and 249.3±16.12 mm2, respectively; The occurrence rate of complications in observation group was 30 %, while in control group was 56.7 %; The incidence of adverse drug reactions in both groups was basically similar (p>0.05). Minocycline has a definite effect on patients with diabetic retinopathy. It can improve the vision of diabetic retinopathy patients; effectively reduce the stages of diabetic retinopathy, the leakage area of fluorescein in retinal neovascularization and the occurrence of related complications. It has no obvious adverse reactions and is worthy of clinical promotion.
AbstractThe pathogenesis of diabetic retinopathy is complicated.The vast network of multiple factors including unifying mechanism,inflammatory reaction,neuron degeneration and metabolic memory of glucose,and the four established pathogenic molecular pathways are hotspots of mechanism research for diabetic retinopathy.Nevertheless,these researches may be only one corner of the iceberg of DR mechanism,and we still face enormous challenges in DR mechanism research.Collaboration with multiple disciplines to study the relationship between DR and diabetes and other systemic diseases,search novel therapy targets may increase the result in an unexpected windfall for DR basic research.
Key words:
Diabetic retinopathy/pathophysiology; Editorial
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
